Comparative Pharmacology
Head-to-head clinical analysis: CLOFARABINE versus ELAHERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOFARABINE versus ELAHERE.
CLOFARABINE vs ELAHERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
ELAHERE (mirvetuximab soravtansine) is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). It consists of a humanized anti-FRα antibody conjugated to the maytansinoid DM4, a microtubule inhibitor. Upon binding to FRα on tumor cells, the ADC is internalized and releases DM4, which binds to tubulin and disrupts microtubule polymerization, leading to cell cycle arrest and apoptosis.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
6 mg/kg adjusted ideal body weight intravenously every 3 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Clinical Note
moderateClofarabine + Digoxin
"Clofarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateClofarabine + Digitoxin
"Clofarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateClofarabine + Deslanoside
"Clofarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateClofarabine + Acetyldigitoxin
"Clofarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Terminal half-life approximately 6.2 days (range 3.7-9.5 days) after IV administration; supports every-3-week dosing interval.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Fecal (approximately 80%) as unchanged drug; renal (approximately 8%) as unchanged drug and metabolites.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent